Gantenerumab

Type: Product
Name: Gantenerumab
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

Market Report, "Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022", Published

Boston, MA -- ( SBWIRE ) -- 04/21/2014 -- The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF ... [Published SBWire - Apr 22 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

This Forgotten Pharma Could Be a Hit for Your Portfolio

Within the world of Big Pharma,  Roche ( NASDAQOTH: RHHBY     ) offers a pretty compelling mix. Not only does Roche have one of the strongest oncology platforms today, it also offers one of the deepest pipelines. The company's non-oncology pipeline is ... [Published Motley Fool Discussion Boards - Apr 15 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

The Proving Ground

What are the qualities that go into a top life science research university?Universities are primarily thought of as training grounds—a place for students to learn the concepts they need to succeed in their careers. But for many universities, they’re also ... [Published Laboratory Equipment - Apr 09 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 1 reports

New Market Study Published: Entyvio (Crohn's Disease) - Forecast and Market Analysis to 2022

Boston, MA -- ( SBWIRE ) -- 03/25/2014 -- The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF ... [Published SBWire - Mar 26 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

"Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022" Now Available at Fast Market Research

Boston, MA -- ( SBWIRE ) -- 03/24/2014 -- The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF ... [Published SBWire - Mar 24 2014]
First reported Mar 02 2014 - Updated Mar 02 2014 - 1 reports

Delivery system for cytotoxic drugs by bispecific antibody pretargeting

The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated ... [Published PharmCast - Mar 02 2014]

Quotes

...In his inaugural address, Gilman promoted "the encouragement of research; the promotion of young men; and the advancement of individual scholars, who by their excellence will advance the sciences they pursue and the society where they dwell" as his goals for the school

More Content

All (6) | News (6) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Market Report, "Prochymal (Crohn's Disease) - F... [Published SBWire - Apr 22 2014]
This Forgotten Pharma Could Be a Hit for Your P... [Published Motley Fool Discussion Boards - Apr 15 2014]
The Proving Ground [Published Laboratory Equipment - Apr 09 2014]
New Market Study Published: Entyvio (Crohn's Di... [Published SBWire - Mar 26 2014]
"Stelara (Crohn's Disease) - Forecast and Marke... [Published SBWire - Mar 24 2014]
Delivery system for cytotoxic drugs by bispecif... [Published PharmCast - Mar 02 2014]
1
In Focus
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.